Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

To combat the significant myelosuppression from the standard 28-day venetoclax cycle in AML, many clinicians are adopting a strategy of performing a bone marrow biopsy around day 21 and pausing the drug if blast clearance is achieved to allow for hematologic recovery.

The anemia seen in myelofibrosis patients on ruxolitinib is not just a drug side effect but an interaction with the underlying disease. This is proven by the fact that polycythemia vera patients on the same drug do not become anemic, showing the myelofibrotic marrow is uniquely susceptible to the drug's effects.

While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.

In patients with systemic mastocytosis and an associated hematologic neoplasm (SM-AHN), the primary clinical challenge is determining which disease component is driving the main problems, such as cytopenias. This is critical because KIT inhibitors treat the SM, but the AHN may require a completely different therapy.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

Clinicians can differentiate side effects based on their profile: "-itis" symptoms (colitis, pneumonitis) suggest immunotherapy, while cytopenias and neuropathy point to chemotherapy. Response to steroids is a key diagnostic clue for immune-related events.

Despite being advanced targeted therapies, TROP2-directed ADCs present complex safety profiles. Oncologists must manage classic chemotherapy side effects like nausea and cytopenias alongside unique, serious toxicities including stomatitis, ocular issues, and potentially fatal interstitial lung disease, requiring specialized patient monitoring and counseling.